H Lundbeck A/S (HLUN-B)
Nasdaq Copenhagen · Denmark · prices in DKK · close of 27 Oct 2026
Key indicators
| Last close | DKK 52.25 |
|---|---|
| 52-week range | 35.30 – 53.10 |
| Return, 1 month / 3 months | +15.4% / +25.1% |
| Return, 1 year / 3 years | +16.5% / +55.4% |
| Trend | Uptrend |
| RSI (14) | 79 |
| Volatility (1 year) | 29.0% |
| Worst drawdown (1 year) | -21.9% |
| Average daily value traded | 33.08M DKK |
| Dividend yield | 2.2% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
H Lundbeck is a Danish pharmaceutical company focused on medicines for disorders of the brain. It develops and supplies prescription treatments for conditions such as depression, schizophrenia and other psychiatric and neurological illnesses. Its customers are doctors, hospitals and healthcare systems that prescribe and dispense these medicines to patients. The company is based in Copenhagen, Denmark, and its products reach markets in many countries around the world.
H Lundbeck A/S trades under the code HLUN-B on the Nasdaq Copenhagen in Denmark, with its price quoted in Danish kroner (DKK). Our dividend records, which start in 2019, show payments in 4 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
H Lundbeck A/S (HLUN-B) trades on the Nasdaq Copenhagen in Denmark. It last closed at DKK 52.25 on 27 October 2026.
Its price-based Market X-Ray is 69 out of 100 (a fair price profile), ranking 38 of 164 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 16.5% and over the last three months it rose 25.1%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Nasdaq Copenhagen
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 85 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 24.2% | ||
| From 52-week high | -0.4% | ||
| Momentum | 73 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 25.1% | ||
| 6-month return | 18.9% | ||
| 12-month return, skipping the last month | 0.9% | ||
| Stability (higher is calmer) | 56 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 29.0% | ||
| Worst drawdown, 1 year (smaller is calmer) | -21.9% | ||
| Liquidity | 82 · Strong | Trades actively. | |
| Average daily value traded | 33.08M DKK | ||
| Zero-volume days | 0.0% | ||
| Income | 36 · Weak | Dividend is small or irregular. | |
| Dividend yield | 2.2% | ||
| Years with dividends | 4 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
- Liquidity: Trades actively.
Weak spots
- Income: Dividend is small or irregular.
Returns
| 1 week | +7.2% |
|---|---|
| 1 month | +15.4% |
| 3 months | +25.1% |
| 6 months | +18.9% |
| 1 year | +16.5% |
| 3 years | +55.4% |
| 5 years | +64.7% |
Signals
| 50-day / 200-day average | 44.83 / 42.06 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | Yes |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 1.17 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 19 Mar 2026 | DKK 1.1500 |
| 27 Mar 2025 | DKK 0.9500 |
| 21 Mar 2024 | DKK 0.7000 |
| 22 Mar 2023 | DKK 0.5800 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Nasdaq Copenhagen; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.